| Primary information |
|---|
| sequence ID | Seq_5623 |
| Peptide sequence | NGFKSHALQLN |
| CancerPDF_ID | CancerPDF_ID34, CancerPDF_ID880, |
| PMID | 16896061,19795908 |
| Protein Name | Complement C4 precursor,Complement C4-B |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN |
| Fluid | Serum,Plasma |
| M/Z | 1228.65,614.82 |
| Charge | 1,2 |
| Mass (in Da) | 1228.64,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring) |
| Labelled/Label Free | Label Free,Labelled |
| FDR | NA,less than 7% |
| CancerPDF_ID | CancerPDF_ID34, CancerPDF_ID880, |
| p-Value | 1.00E-05,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software |
| Length | 11,11 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP) |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database |
| Modification | NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients" |
| Regulation | NA,NA |
| Validation | Independent validation,NA |
| Sensitivity | 95% on independent dataset,NA |
| Specificity | 95% on independent dataset,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |